“ROSUVASTATIN” & “TELMISARTAN” ” for Cipla pharmaceutical in the pharmaceutical industry conducted
at Coimbatore, Tamilnadu
Submitted in partial fulfillment of the award of the degree of
Master of Business Administration
Mahatma Gandhi University
Under the Guidance of
ANU ANNA ANTHONY
Sree Narayana Guru Institute of Science & Technology
North Paravur,Ernakulam 2005-2007
This is to certify that the project titled “Competitive analysis of “ROSUVASTATIN” & “TELMISARTAN” in the pharmaceutical industry conducted at Coimbatore, Tamilnadu” submitted by MANISH.K.B In partial fulfillment of the requirement for the award of the degree Master of Business Administration (MBA) programme of Sree Narayana Guru Institute of Science and Technology (SNGIST) affiliated to Mahatma Gandhi University during 2005 -2007, is a bonafide record of work done by him under my supervision and guidance and this certificate is not issued to endorse the opinion and results expressed in this report.
Anu Anna AnthonyMs Ranjini…….
Faculty Guide HOD
Dr. Anandakuttan B Unnithan
I would like to express my sincere thanks to Dr. Anandakuttan B. Unnithan, B.Tech, M.B.A director of Sree Narayana Guru Institute of Science and Technology North Paravur.
I am very thankful to Mrs.Renjini Jaikumar, M.B.A Head of the Department of Management for her kind and help and encouragement.
I wish to express my heartiest thanks to Mrs. Anu Anna Anthony M.B.A, for her valuable guidance suggestion and kind encouragement through the entire phase of the project.
I wish to express my sincere thanks to Mr. FIROZ the area manager and all other staff of Cipla, Coimbatore branch for providing valuable support for the project.
I hereby declare that this is a bonafide record of the work done by me in partial fulfillment of the requirement for the award of the degree Master of Business Administration (MBA) of Mahatma Gandhi University and that this report has not been submitted to any university for the award of any degree to the best of my knowledge and belief
TABLE OF CONTENT
The Indian Pharmaceutical Industry is expected to undergo phenomenal change when international patent laws will be implemented. India’s domestic pharmaceutical companies have experienced a significant increase in R&D spending to be competitive in the world market. Although the Indian pharmaceutical market is very small and does not have enough funding for drug discovery programs, India has well-educated scientists, a well-established computer industry, and technological know-how for the manufacture of bulk drugs and formulations. The American pharmaceutical industry has played a pioneering role in the development of the drug industry through in-depth, timely, and useful research and bulk manufacturing of drug products. Although the US pharmaceutical industry is enjoying the leadership position, it can no longer be content to focus only on the US, Japanese, and European markets.
Two recent articles that analyzed the Chinese and Hungarian pharmaceutical markets showed that during the 1990s, the Chinese pharmaceutical market experienced overestimated demand and severe under capacity use, and the Hungarian pharmaceutical market suffered setbacks in the same decade and was forced to adopt new strategies to revive the industry (1,2). India, being the second...